INFOGRAPHIC: A Heterogenous Disease with Varied Clinical Outcomes: HR+/HER2- MBC
This infographic is intended to educate healthcare providers on the heterogeneity of HR+, HER2- metastatic breast cancer, factors more likely to confer a poorer prognosis, and information on the standard first-line treatment for patients.
Date of Last Review: March 11, 2024
Are you satisfied with this content?